Trial reportAfrican health sciences2019
A randomized controlled clinical trial evaluating the effect of
Trial report in African health sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Fenugreek Is Superior to Guar Gum, Locust Bean Gum and Tara Gum for Metabolic Health: A Systematic Review.Nutrients · 2026Pooled it
- Effectiveness and Safety of Ayurvedic Medicines in Type 2 Diabetes Mellitus Management: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2022Pooled it
- Efficacy and Sustainability of Diabetes-Specific Meal Replacement on Obese and Overweight Type-2 Diabetes Mellitus Patients: Study Approaches for a Randomised Controlled Trial and Impact of COVID-19 on Trial Progress.International journal of environmental research and public health · 2022Trial
- Exploring the Adverse Effects of Fenugreek in Humans: A Scoping Review.Iranian journal of medical sciences · 2026Article
- Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Comprehensive review of opportunities and challenges of ethnomedicinal plants for managing type 2 diabetes.Heliyon · 2024Review
- Antidiabetic potential of fenugreek (Food science & nutrition · 2024Review
- Pharmacological Activities, Therapeutic Effects, and Mechanistic Actions of Trigonelline.International journal of molecular sciences · 2024Review
- A randomized double blind placebo controlled trial to assess the safety and efficacy of a patented fenugreek (Food & nutrition research · 2024Article
- Article
- Validation of standardized polyherbal formulation in the management of type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial.Journal of diabetes and metabolic disorders · 2023Article
- Role of Fenugreek, Cinnamon,Pharmaceuticals (Basel, Switzerland) · 2023Review
- Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal.Inflammopharmacology · 2023Review
- Promoting cardioprotection with fenugreek: Insights from CoClIranian journal of basic medical sciences · 2023Article
- Review
- An Exploratory Study of the Safety and Efficacy of aPharmaceutics · 2022Article
- The role of selected nutraceuticals in management of prediabetes and diabetes: An updated review of the literature.Phytotherapy research : PTR · 2022Review
- Improved glycemic status, insulin resistance and inflammation after receiving oral oleoylethanolamide supplement in people with prediabetes: a randomized controlled trial.Diabetology & metabolic syndrome · 2022Article
- West meets east: open up a dialogue on phytomedicine.Chinese medicine · 2021Review
- Decreased insulin resistance in diabetic patients by influencing Sirtuin1 and Fetuin-A following supplementation with ellagic acid: a randomized controlled trial.Diabetology & metabolic syndrome · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHerbal medicines long have been used in the management of diabetes mellitus (DM).
objectiveThis study was conducted to ascertain if fenugreek compared with glibenclamide had any impacts on controlling blood glucose in patients with uncontrolled type II DM on conventional therapy.
methodsA total of 12 patients with uncontrolled DM and on metformin were recruited and divided into two groups. Patients in group 1 received 2 g fenugreek per day, whereas those in group 2 received glibenclamide 5 mg once daily. The impacts of fenugreek on the glycemic control and lipid profile were measured before initiation of the regimen and then after 12 weeks.
resultsOnly 9 of the 12 study participants completed the study. Fenugreek at 2 g/day caused an insignificant drop in fasting blood glucose (P = 0.63), but the fasting insulin level increased significantly (P = 0.04). The ratio of high- to low-density lipoprotein was significantly decreased from before to after treatment (P = 0.006). Fenugreek did not cause any notable adverse impacts on hepatic and renal functions throughout the study.
conclusionFenugreek could be used as adjuvant therapy to anti-diabetic drugs to control blood glucose, and further studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.